{
    "xml": "<topic id=\"PHP2213\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/chlorpromazine-hydrochloride\" basename=\"chlorpromazine-hydrochloride\" title=\"CHLORPROMAZINE HYDROCHLORIDE\">\n<title>CHLORPROMAZINE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_374\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/chlorpromazine\">Chlorpromazine</xref>\n</p>\n<data name=\"vtmid\">47331002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP37651\" outputclass=\"indicationsAndDose\" rev=\"1.35\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia and other psychoses</p>\n<p outputclass=\"therapeuticIndication\">Mania</p>\n<p outputclass=\"therapeuticIndication\">Short-term adjunctive management of severe anxiety</p>\n<p outputclass=\"therapeuticIndication\">Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg 3 times a day, adjusted according to response, alternatively initially 75&#8239;mg once daily, adjusted according to response, dose to be taken at night; maintenance 75&#8211;300&#8239;mg daily, increased if necessary up to 1&#8239;g daily, this dose may be required in psychoses, take a third to half adult dose in the elderly and debilitated patients.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By rectum</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8239;mg every 6&#8211;8&#8239;hours, dose expressed as chlorpromazine base.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Intractable hiccup</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>25&#8211;50&#8239;mg 3&#8211;4 times a day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Relief of acute symptoms of psychoses (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>25&#8211;50&#8239;mg every 6&#8211;8&#8239;hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting of terminal illness (where other drugs have failed or are not available)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;5 years</p>\n<p>500&#8239;micrograms/kg every 4&#8211;6&#8239;hours; maximum 40&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 6&#8211;11 years</p>\n<p>500&#8239;micrograms/kg every 4&#8211;6&#8239;hours; maximum 75&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>10&#8211;25&#8239;mg every 4&#8211;6&#8239;hours.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8211;25&#8239;mg every 4&#8211;6&#8239;hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;5 years</p>\n<p>500&#8239;micrograms/kg every 6&#8211;8&#8239;hours; maximum 40&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 6&#8211;11 years</p>\n<p>500&#8239;micrograms/kg every 6&#8211;8&#8239;hours; maximum 75&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 25&#8239;mg, then 25&#8211;50&#8239;mg every 3&#8211;4&#8239;hours until vomiting stops.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg, then 25&#8211;50&#8239;mg every 3&#8211;4&#8239;hours until vomiting stops.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By rectum</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8239;mg every 6&#8211;8&#8239;hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>For equivalent therapeutic effect 100&#8239;mg chlorpromazine base given <i>rectally</i> as a suppository &#8801; 20&#8211;25&#8239;mg chlorpromazine hydrochloride <i>by intramuscular injection</i> &#8801; 40&#8211;50&#8239;mg of chlorpromazine base or hydrochloride given <i>by mouth</i>.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37624\" outputclass=\"unlicensedUse\" rev=\"1.8\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Rectal route is not licensed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37677\" outputclass=\"contraindications\" rev=\"1.23\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">hypothyroidism</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37687\" outputclass=\"cautions\" rev=\"1.6\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diabetes</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37634\" outputclass=\"sideEffects\" rev=\"1.20\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"specificity\">When used for <ph outputclass=\"indication\">Nausea and vertigo</ph>\n</p>\n<p outputclass=\"title\">Acute dystonic reactions</p>\n<p>Phenothiazines can induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37647\" outputclass=\"pregnancy\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37692\" outputclass=\"breastFeeding\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n<p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37662\" outputclass=\"hepaticImpairment\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37640\" outputclass=\"renalImpairment\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37623\" outputclass=\"monitoringRequirements\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use</p>\n<p>Patients should remain supine, with blood pressure monitoring for 30 minutes after intramuscular injection.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37665\" outputclass=\"handlingAndStorage\" rev=\"1.7\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Handling and storage</title>\n<body>\n<section>\n<sectiondiv>\n<p>Owing to the risk of contact sensitisation, pharmacists, nurses, and other health workers should avoid direct contact with chlorpromazine; tablets should not be crushed and solutions should be handled with care.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2213-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/chlorpromazine-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: suppository, oral suspension, oral solution, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74975\" title=\"Tablet\" namespace=\"/drugs/chlorpromazine-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74998\" title=\"Oral solution\" namespace=\"/drugs/chlorpromazine-hydrochloride/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74980\" title=\"Solution for injection\" namespace=\"/drugs/chlorpromazine-hydrochloride/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"2\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"3\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"1\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"1\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_374\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/chlorpromazine\" title=\"Chlorpromazine\" count=\"1\" rel=\"link\">Chlorpromazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74975\" namespace=\"/drugs/chlorpromazine-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74998\" namespace=\"/drugs/chlorpromazine-hydrochloride/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74980\" namespace=\"/drugs/chlorpromazine-hydrochloride/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2213",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/chlorpromazine-hydrochloride",
    "basename": "chlorpromazine-hydrochloride",
    "title": "CHLORPROMAZINE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_374",
            "label": "Chlorpromazine"
        }
    ],
    "vtmid": "47331002",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia and other psychoses",
                        "html": "Schizophrenia and other psychoses"
                    },
                    {
                        "textContent": "Mania",
                        "html": "Mania"
                    },
                    {
                        "textContent": "Short-term adjunctive management of severe anxiety",
                        "html": "Short-term adjunctive management of severe anxiety"
                    },
                    {
                        "textContent": "Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour",
                        "html": "Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour"
                    }
                ],
                "specificity": {
                    "routes": [
                        "rectum"
                    ],
                    "textContent": "By rectum",
                    "html": "By rectum"
                },
                "adult": [
                    {
                        "textContent": "Initially 25 mg 3 times a day, adjusted according to response, alternatively initially 75 mg once daily, adjusted according to response, dose to be taken at night; maintenance 75&#8211;300 mg daily, increased if necessary up to 1 g daily, this dose may be required in psychoses, take a third to half adult dose in the elderly and debilitated patients.",
                        "html": "<p>Initially 25&#8239;mg 3 times a day, adjusted according to response, alternatively initially 75&#8239;mg once daily, adjusted according to response, dose to be taken at night; maintenance 75&#8211;300&#8239;mg daily, increased if necessary up to 1&#8239;g daily, this dose may be required in psychoses, take a third to half adult dose in the elderly and debilitated patients.</p>"
                    },
                    {
                        "textContent": "100 mg every 6&#8211;8 hours, dose expressed as chlorpromazine base.",
                        "html": "<p>100&#8239;mg every 6&#8211;8&#8239;hours, dose expressed as chlorpromazine base.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Intractable hiccup",
                        "html": "Intractable hiccup"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "25&#8211;50 mg 3&#8211;4 times a day.",
                        "html": "<p>25&#8211;50&#8239;mg 3&#8211;4 times a day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Relief of acute symptoms of psychoses (under expert supervision)",
                        "html": "Relief of acute symptoms of psychoses (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "25&#8211;50 mg every 6&#8211;8 hours.",
                        "html": "<p>25&#8211;50&#8239;mg every 6&#8211;8&#8239;hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting of terminal illness (where other drugs have failed or are not available)",
                        "html": "Nausea and vomiting of terminal illness (where other drugs have failed or are not available)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "rectum"
                    ],
                    "textContent": "By rectum",
                    "html": "By rectum"
                },
                "child": [
                    {
                        "textContent": "500 micrograms/kg every 4&#8211;6 hours; maximum 40 mg per day.",
                        "html": "<p>500&#8239;micrograms/kg every 4&#8211;6&#8239;hours; maximum 40&#8239;mg per day.</p>",
                        "ageGroup": "1&#8211;5 years"
                    },
                    {
                        "textContent": "500 micrograms/kg every 4&#8211;6 hours; maximum 75 mg per day.",
                        "html": "<p>500&#8239;micrograms/kg every 4&#8211;6&#8239;hours; maximum 75&#8239;mg per day.</p>",
                        "ageGroup": "6&#8211;11 years"
                    },
                    {
                        "textContent": "10&#8211;25 mg every 4&#8211;6 hours.",
                        "html": "<p>10&#8211;25&#8239;mg every 4&#8211;6&#8239;hours.</p>",
                        "ageGroup": "12&#8211;17 years"
                    },
                    {
                        "textContent": "500 micrograms/kg every 6&#8211;8 hours; maximum 40 mg per day.",
                        "html": "<p>500&#8239;micrograms/kg every 6&#8211;8&#8239;hours; maximum 40&#8239;mg per day.</p>",
                        "ageGroup": "1&#8211;5 years"
                    },
                    {
                        "textContent": "500 micrograms/kg every 6&#8211;8 hours; maximum 75 mg per day.",
                        "html": "<p>500&#8239;micrograms/kg every 6&#8211;8&#8239;hours; maximum 75&#8239;mg per day.</p>",
                        "ageGroup": "6&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 25 mg, then 25&#8211;50 mg every 3&#8211;4 hours until vomiting stops.",
                        "html": "<p>Initially 25&#8239;mg, then 25&#8211;50&#8239;mg every 3&#8211;4&#8239;hours until vomiting stops.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "10&#8211;25 mg every 4&#8211;6 hours.",
                        "html": "<p>10&#8211;25&#8239;mg every 4&#8211;6&#8239;hours.</p>"
                    },
                    {
                        "textContent": "Initially 25 mg, then 25&#8211;50 mg every 3&#8211;4 hours until vomiting stops.",
                        "html": "<p>Initially 25&#8239;mg, then 25&#8211;50&#8239;mg every 3&#8211;4&#8239;hours until vomiting stops.</p>"
                    },
                    {
                        "textContent": "100 mg every 6&#8211;8 hours.",
                        "html": "<p>100&#8239;mg every 6&#8211;8&#8239;hours.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "For equivalent therapeutic effect 100 mg chlorpromazine base given rectally as a suppository &#8801; 20&#8211;25 mg chlorpromazine hydrochloride by intramuscular injection &#8801; 40&#8211;50 mg of chlorpromazine base or hydrochloride given by mouth.",
                "html": "<p>For equivalent therapeutic effect 100&#8239;mg chlorpromazine base given <i>rectally</i> as a suppository &#8801; 20&#8211;25&#8239;mg chlorpromazine hydrochloride <i>by intramuscular injection</i> &#8801; 40&#8211;50&#8239;mg of chlorpromazine base or hydrochloride given <i>by mouth</i>.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Rectal route is not licensed.",
                "html": "<p>Rectal route is not licensed.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "hypothyroidism",
                "html": "hypothyroidism"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diabetes",
                "html": "Diabetes"
            }
        ]
    },
    "sideEffects": {
        "advice": [
            {
                "type": "advice",
                "specificity": {
                    "textContent": "When used for Nausea and vertigo",
                    "html": "When used for <ph outputclass=\"indication\">Nausea and vertigo</ph>",
                    "indications": [
                        "Nausea and vertigo"
                    ]
                },
                "title": "Acute dystonic reactions",
                "textContent": "Phenothiazines can induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.",
                "html": "<p>Phenothiazines can induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.\n\nPhenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p><p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma; phenothiazines are hepatotoxic.",
                "html": "<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "With intramuscular use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use",
                    "routes": [
                        "intramuscular"
                    ]
                },
                "textContent": "Patients should remain supine, with blood pressure monitoring for 30 minutes after intramuscular injection.",
                "html": "<p>Patients should remain supine, with blood pressure monitoring for 30 minutes after intramuscular injection.</p>"
            }
        ]
    },
    "handlingAndStorage": {
        "handlingAndStorage": [
            {
                "type": "handlingAndStorage",
                "textContent": "Owing to the risk of contact sensitisation, pharmacists, nurses, and other health workers should avoid direct contact with chlorpromazine; tablets should not be crushed and solutions should be handled with care.",
                "html": "<p>Owing to the risk of contact sensitisation, pharmacists, nurses, and other health workers should avoid direct contact with chlorpromazine; tablets should not be crushed and solutions should be handled with care.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "suppository",
                "oral suspension",
                "oral solution",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74975",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74998",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74980",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_374",
                "label": "Chlorpromazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74975",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74998",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74980",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}